Likewise, exon 20 insertions in the EGFR family member ErbB2 (found in ∼2% of NSCLC) confer resistance to these drugs (Wang et al, 2006), making it imperative to identify alternative strategies to inhibit the activity and signalling capability of these ErbB mutants (Shimamura et al, 2006). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.